Heat shock protein 90 (HSP90) is a highly conserved protein that oversees the proper folding and stabilization of numerous client proteins, many of which are involved in signaling pathways related to cell growth, survival, and stress responses. As organisms age, the expression and functionality of HSP90 can decline, leading to the accumulation of misfolded proteins and cellular dysfunction. This decline has been linked to various age-related diseases.
Fig. 1 HSP90 and its homologs are involved in cardiovascular diseases (CVDs) and heart senescence. (Dabravolski SA, et al., 2022)
CD BioSciences aims to help clients develop innovative anti-aging drugs targeting HSP90. Our integrated approach to target identification, drug discovery, and analytical services makes us a trusted partner in promoting healthy aging.
How Do We Identify HSP90 as an Anti-Aging Target?
CD BioSciences helps clients identify and validate HSP90 as an anti-aging target. We utilize bioinformatics tools to analyze large datasets from genomic and proteomic studies to identify potential Hsp90 client proteins that may be involved in aging processes. By elucidating the network of protein interactions with HSP90, we can identify drug candidates that exhibit the potential for anti-aging effects.
Types of Anti-Aging Drugs Targeting HSP90 We Can Develop
We are committed to helping clients develop different types of drugs targeting HSP90. Our high-throughput screening (HTS) technology allows clients to evaluate drug candidates that inhibit HSP90. We help clients systematically modify the chemical structure of drug candidates to identify modifications that enhance potency and specificity for HSP90 inhibition. We also employ surface plasmon resonance (SPR) to help clients study the binding affinity of compounds to HSP90 for further optimization.
- HSP90 inhibitors. We help clients discover and develop senolytic drugs that can inhibit HSP90 activity, potentially restoring its normal activity in aged cells. The senolytic drugs potentially improve the cellular stress response, enhancing longevity.
- Combination therapies. We also assist clients in exploring combinations of HSP90 inhibitors with other anti-aging drugs that may have synergistic effects.
How Do We Evaluate the Effects of Anti-Aging Drugs Targeting HSP90?
Evaluation of the effects of drugs on eliminating senescent cells
We help clients analyze the effects of anti-aging drugs targeting HSP90 on promoting the clearance of senescent cells across various cell types and species. Our services are crucial for determining the broad applicability of the drugs as anti-aging therapeutics.
Evaluation of the effects of drugs on reducing senescence markers
We offer analyses of the effects of anti-aging drugs targeting HSP90 on key senescence markers, such as p16INK4a, p21CIP1, and SASP factors. The reduction of these markers upon treatment with anti-aging drugs targeting HSP90 indicates a potential anti-senescence effect.
Evaluation of the effects of drugs on downregulating the anti-apoptotic pathways
CD BioSciences assesses the impact of anti-aging drugs targeting HSP90 on anti-apoptotic pathways, such as the PI3K/Akt pathway, to assess their efficacy as anti-aging drugs.
Targeting HSP90 represents a promising avenue for the development of anti-aging therapeutics. CD BioSciences is dedicated to identifying and developing effective anti-aging drugs targeting HSP90 using advanced screening techniques. If you are interested in our services, please feel free to contact us or make an online inquiry.
References
- Fuhrmann-Stroissnigg H, et al. Hsp90 inhibitors as senolytic drugs to extend healthy aging. Cell Cycle, 2018, 17 (9): 1048-1055.
- Dabravolski SA, et al. Heat Shock Protein 90 as Therapeutic Target for CVDs and Heart Ageing. Int J Mol Sci, 2022, 23 (2): 649.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
